Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stable fat emulsion containing prostaglandin e1

A fat emulsion and prostaglandin technology, applied in the field of fat emulsion, can solve the problems of short effective time and increased pharmaceutical management cost, and achieve the effect of high stability

Inactive Publication Date: 2010-06-16
MITSUBISHI TANABE PHARMA CORP +1
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the aforementioned PGE 1 Lipidated formulations due to PGE as an active ingredient 1 It is easy to decompose in the solution, so in order to avoid freezing, it must be stored in the dark at 5°C, the effective time is shorter than ordinary preparations, and it is stable for 1 year
Such preparations lead to an increase in drug management costs in the distribution stage and clinical sites, so it is desired to develop a drug with a long effective time in relation to the reduction of drug management costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable fat emulsion containing prostaglandin e1
  • Stable fat emulsion containing prostaglandin e1
  • Stable fat emulsion containing prostaglandin e1

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0032] Dissolving alprostadil (PGE) in refined soybean oil 1 ), oleic acid, and egg yolk lecithin from which phosphatidylethanolamine (PE) has been removed, add a mixture of glycerin and distilled water for injection prepared separately, stir with a homogenizer, and prepare a suspension. The resulting suspension was emulsified by a Manton-Gaulin type emulsifier (manufactured by Manton-Gaulin), and the pH was adjusted to 4.90 using sodium hydroxide and hydrochloric acid. The formulated emulsion is filled into Silicoat ampoules (manufactured by Fuji Glass, and the thickness of the ampoule is 70 to 100 In the glass ampoule with a silicon oxide protective film), the void part of the ampoule was replaced with nitrogen, and sealed by fusing. The obtained ampoule was sterilized at 125° C. for 2.2 minutes using a high-pressure steam sterilizer to obtain the fat emulsion of the present invention.

example 2

[0034] An emulsion was formulated in the same manner as in Example 1, adjusted to pH 5.01 with sodium hydroxide, filled and sealed in a Silicoat ampoule and sterilized in the same manner as in Example 1 to obtain the fat emulsion of the present invention.

example 3

[0036] An emulsion was formulated in the same manner as in Example 1, and the pH was adjusted to 5.15 using sodium hydroxide. Then, it was filled and sealed in a Silicoat ampoule in the same manner as in Example 1, and sterilized to obtain the fat emulsion of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a fat emulsion containing a compound having prostaglandin E1 activity, which fat emulsion is hermetically sealed in a glass container and then heat sterilized. The residual amount of prostaglandin E1 activity after 16-month storage at 5 DEG C is not less than 65% but not more than 100% of the prostaglandin E1 activity at the beginning of storage.

Description

technical field [0001] The present invention relates to containing prostaglandin E 1 stable fat emulsion. Background technique [0002] Prostaglandin E 1 (hereinafter, sometimes referred to as "PGE 1 ") The general name is that Alprostadil (Alprostadil) has a strong vasodilator effect and inhibits platelet aggregation, and is effective for improving chronic arterial occlusions (Buerger's disease, obliterative arteriosclerosis) when extremity ulcers and quiet It is effective in improving the pain of the patient, the improvement of the skin ulcer of the mobile systemic cured disease, the improvement of the skin ulcer of the diabetes, etc., so it is used in clinical practice. As a product containing prostaglandin E 1 formulations known to require dissolution of PGE in fine fat particles 1 So-called lipidation preparations (for example, "Liple Injection", manufactured and sold by Mitsubishi Tanabe Pharmaceutical Co., Ltd.). This preparation is based on the fact that fat par...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5575A61K9/10A61P7/02A61K9/08A61K17/02
CPCA61K31/5575A61K9/107A61P17/02A61P43/00A61P7/02A61P9/08A61K47/10A61K47/12A61K47/24A61K47/46
Inventor 福山刚之尾崎和彦平井贤一
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com